Role of vasopressin in cardiovascular response to central cholinergic stimulation in rats.
The cardiovascular effects of centrally administered cholinomimetics were examined in conscious Long-Evans and Brattleboro rats. Carbachol (1 microgram/kg) or physostigmine (50 micrograms/kg) induced a long-lasting increase in blood pressure and a decrease in heart rate in Long-Evans rats whereas no bradycardia was observed in Brattleboro rats, and the pressor response was significantly less than that in Long-Evans rats. The cardiovascular responses to nicotine (30 micrograms/kg) in Brattleboro rats were not different from those in Long-Evans rats. Intravenous vasopressin antagonist, d(CH2)5Tyr(Me) arginine vasopressin, significantly attenuated the pressor response and eliminated the bradycardic response to carbachol in Long-Evans rats. However, the pressor response to carbachol in Brattleboro rats was still significantly less than that in Long-Evans rats treated with vasopressin antagonist. Intravenous phentolamine partially inhibited the pressor response to carbachol in Long-Evans rats and completely eliminated it in Brattleboro rats. Combined intravenous treatment with phentolamine and vasopressin antagonist completely eliminated the pressor response to carbachol in Long-Evans rats. Centrally administered methylatropine eliminated either the hypertensive or bradycardic response to carbachol in Long-Evans rats. These results indicate that the pressor and bradycardic response to carbachol or physostigmine is mediated by the central muscarinic receptor mechanism. Hypertensive response to intracerebroventricularly administered carbachol in normal rats is mediated both by an increase in central sympathetic outflow and in circulating vasopressin. The bradycardia seems to be mediated mainly by vasopressin.
Imai
Y
Y
Department of Medicine, Tohoku University School of Medicine, Sendai, Japan.
Abe
K
K
Sasaki
S
S
Minami
N
N
Munakata
M
M
Yumita
S
S
Nobunaga
T
T
Sekino
H
H
Yoshinaga
K
K
D000818:Animals; D001127:Arginine Vasopressin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors; D001286:Atropine Derivatives / Q000494:pharmacology; D001341:Autonomic Nervous System / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D001919:Bradycardia / Q000503:physiopathology; D002217:Carbachol / Q000008:administration & dosage / Q000494:pharmacology; D002320:Cardiovascular Physiological Phenomena; D002319:Cardiovascular System / Q000187:drug effects; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology; D006973:Hypertension / Q000503:physiopathology; D007276:Injections, Intraventricular; D008297:Male; D009538:Nicotine / Q000494:pharmacology; D010276:Parasympatholytics / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D010830:Physostigmine / Q000494:pharmacology; D051381:Rats; D011910:Rats, Brattleboro; D014667:Vasopressins / Q000037:antagonists & inhibitors / Q000097:blood* / Q000494:pharmacology
D001286:Atropine Derivatives; D010276:Parasympatholytics; D014667:Vasopressins; D001127:Arginine Vasopressin; D009538:Nicotine; C025043:vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine-; C006649:methylatropine; D002217:Carbachol; D010830:Physostigmine; D003894:Deamino Arginine Vasopressin; D010646:Phentolamine